Back to News
Market Impact: 0.15
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Source: PRWeb
Healthcare & Biotech
AbbVie says 20 scientific presentations highlight the breadth of its inflammatory bowel disease research programs. Long-term and real-world data on SKYRIZI (risankizumab) and RINVOQ (upadacitinib) offer additional insight into clinical and endoscopic outcomes; the article excerpt provides no specific results or figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
ABBV0.60
More News
- AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors?
- Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle
- If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
- AI rapidly improving, could vastly boost U.S. GDP, Anthropic's Clark tells policymakers
- Susan Dell is the one running the Dells’ $10 billion giving operation—and her biggest bets are on kids, health care, and UT Austin
- Kenya confirms four more Ebola cases, bringing total to seven
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Financial Research Benchmarks: What the Scores Mean
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper